AARD
Aardvark Therapeutics, Inc.
Price Chart
Latest Quote
$1.24
+0.16 (+14.81%)
Current Price
| Previous Close | $1.08 |
| Open | $1.09 |
| Day High | $1.28 |
| Day Low | $1.09 |
| Volume | 633,193 |
Stock Information
| Shares Outstanding | 21.88M |
| Total Debt | $677K |
| Cash Equivalents | $73.87M |
| Net Income | $-69.89M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $27.14M |
| EPS (TTM) | $-2.38 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-49.56M |
| Income | $-69.89M |
| Book/sh | $3.42 |
| Cash/sh | $3.38 |
| Employees | 28 |
Financial Ratios
| Quick Ratio | 11.57 |
| Current Ratio | 12.63 |
| Debt/Eq | 0.91 |
Returns & Margins
| ROA | -40.38% |
| ROE | -66.02% |
Ownership
| Insider Ownership | 15.77% |
| Institutional Ownership | 52.60% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.54 |
| P/B | 0.36 |
Analyst Data
| Recommendation | buy |
| Target Price | $8.29 |
Technical Indicators
| SMA20 | $4.00 |
| SMA50 | $5.06 |
| SMA200 | $6.52 |
| RSI | 16.06 |
| ATR | 0.5789 |
| Shares Float | 11.01M |
| Short Float | 3.24% |
| Short Ratio | 3.93 |
| Rel Volume | 0.50 |
Performance History
| Week | -68.21% |
| Month | -76.47% |
| Quarter | -76.69% |
| 6 Months | -77.82% |
| YTD | -90.60% |
| Year | -88.41% |
| 10 Years | -91.33% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $1.24 | 633,193 |
| 2026-10-26 | $1.08 | 4,938,300 |
| 2026-10-23 | $1.39 | 16,346,500 |
| 2026-10-22 | $3.95 | 1,415,300 |
| 2026-10-21 | $4.41 | 218,400 |
| 2026-10-20 | $3.90 | 66,700 |
| 2026-10-19 | $3.74 | 129,800 |
| 2026-10-16 | $3.78 | 97,200 |
| 2026-10-15 | $3.86 | 68,800 |
| 2026-10-14 | $3.88 | 126,100 |
| 2026-10-13 | $4.04 | 218,300 |
| 2026-10-12 | $4.45 | 99,900 |
| 2026-10-09 | $4.76 | 140,900 |
| 2026-10-08 | $4.71 | 316,000 |
| 2026-10-07 | $4.96 | 212,000 |
| 2026-10-06 | $5.04 | 251,900 |
| 2026-10-05 | $5.22 | 61,300 |
| 2026-10-02 | $4.99 | 147,700 |
| 2026-10-01 | $5.27 | 47,800 |
| 2026-09-30 | $5.27 | 28,100 |
| 2026-09-29 | $5.35 | 39,600 |
| 2026-09-28 | $5.27 | 60,600 |
About Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on AARD.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $62,725,000 | $22,668,000 | $6,653,000 | $10,874,000 |
| Other Income Expense | $-5,000 | $-334,000 | $-1,978,000 | $-2,810,000 |
| Net Non Operating Interest Income Expense | $5,139,000 | $2,414,000 | $1,423,000 | $120,000 |
| Operating Expense | $62,725,000 | $22,668,000 | $6,653,000 | $10,874,000 |
| General And Administrative Expense | $13,789,000 | $5,305,000 | $2,173,000 | $2,702,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-57,591,000 | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Net Interest Income | $5,139,000 | $2,414,000 | $1,423,000 | $120,000 |
| Interest Income | $5,139,000 | $2,414,000 | $1,423,000 | $120,000 |
| Normalized Income | $-57,586,000 | $-20,254,000 | $-5,230,000 | $-10,754,000 |
| Net Income From Continuing And Discontinued Operation | $-57,591,000 | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Total Operating Income As Reported | $-62,725,000 | $-22,785,000 | $-7,415,000 | $-11,363,000 |
| Net Income Common Stockholders | $-57,591,000 | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Net Income | $-57,591,000 | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Net Income Including Noncontrolling Interests | $-57,591,000 | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Net Income Continuous Operations | $-57,591,000 | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Pretax Income | $-57,591,000 | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Special Income Charges | $0 | $-117,000 | $-762,000 | $-489,000 |
| Interest Income Non Operating | $5,139,000 | $2,414,000 | $1,423,000 | $120,000 |
| Operating Income | $-62,725,000 | $-22,668,000 | $-6,653,000 | $-10,874,000 |
| Per Share | ||||
| Diluted EPS | $-2.93 | $-0.96 | $-0.56 | $-1.39 |
| Basic EPS | $-2.93 | $-0.96 | $-0.56 | $-1.39 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-62,684,000 | $-22,318,000 | $-4,675,000 | $-7,954,000 |
| Total Unusual Items | $-5,000 | $-334,000 | $-1,978,000 | $-2,810,000 |
| Total Unusual Items Excluding Goodwill | $-5,000 | $-334,000 | $-1,978,000 | $-2,810,000 |
| Reconciled Depreciation | $36,000 | $16,000 | $0 | $110,000 |
| EBITDA (Bullshit earnings) | $-62,689,000 | $-22,652,000 | $-6,653,000 | $-10,764,000 |
| EBIT | $-62,725,000 | $-22,668,000 | $-6,653,000 | $-10,874,000 |
| Diluted Average Shares | $19,624,626 | $21,384,377 | $12,909,267 | $9,732,784 |
| Basic Average Shares | $19,624,626 | $21,384,377 | $12,909,267 | $9,732,784 |
| Diluted NI Availto Com Stockholders | $-57,591,000 | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Write Off | $0 | $117,000 | $762,000 | $489,000 |
| Gain On Sale Of Security | $-5,000 | $-217,000 | $-1,216,000 | $-2,321,000 |
| Research And Development | $48,936,000 | $17,363,000 | $4,480,000 | $7,172,000 |
| Selling General And Administration | $13,789,000 | $5,305,000 | $2,173,000 | $2,702,000 |
| Other Gand A | $13,789,000 | $5,305,000 | $2,173,000 | $2,702,000 |
| Provision For Doubtful Accounts | - | $117,000 | $0 | $1,000,000 |
| Other Special Charges | - | - | - | $1,000,000 |
Fetched: 2026-10-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $106,633,000 | $-54,643,000 | $-34,802,000 | $-27,923,000 |
| Total Assets | $117,181,000 | $77,507,000 | $10,536,000 | $16,757,000 |
| Total Non Current Assets | $5,295,000 | $3,370,000 | $168,000 | $266,000 |
| Other Non Current Assets | $4,940,000 | $2,635,000 | $13,000 | $14,000 |
| Current Assets | $111,886,000 | $74,137,000 | $10,368,000 | $16,491,000 |
| Other Current Assets | $1,859,000 | $474,000 | $127,000 | $70,000 |
| Cash Cash Equivalents And Short Term Investments | $110,027,000 | $73,663,000 | $9,989,000 | $16,105,000 |
| Cash And Cash Equivalents | $47,051,000 | $61,641,000 | $9,735,000 | $15,559,000 |
| Prepaid Assets | - | $314,000 | $252,000 | $316,000 |
| Debt | ||||
| Total Debt | $441,000 | $779,000 | $162,000 | $262,000 |
| Long Term Debt And Capital Lease Obligation | $0 | $441,000 | $50,000 | $162,000 |
| Current Debt And Capital Lease Obligation | $441,000 | $338,000 | $112,000 | $100,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $10,548,000 | $132,150,000 | $45,338,000 | $44,680,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $127,223,000 | $43,956,000 | $44,085,000 |
| Current Liabilities | $10,548,000 | $4,927,000 | $1,382,000 | $595,000 |
| Current Deferred Liabilities | $0 | $671,000 | $0 | - |
| Payables And Accrued Expenses | $7,194,000 | $3,693,000 | $1,225,000 | $442,000 |
| Payables | $2,072,000 | $2,298,000 | $1,035,000 | $259,000 |
| Accounts Payable | $2,072,000 | $2,298,000 | $1,035,000 | $259,000 |
| Other Non Current Liabilities | - | $26,000 | $2,000 | $19,000 |
| Equity | ||||
| Common Stock Equity | $106,633,000 | $-54,643,000 | $-34,802,000 | $-27,923,000 |
| Total Equity Gross Minority Interest | $106,633,000 | $-54,643,000 | $-34,802,000 | $-27,923,000 |
| Stockholders Equity | $106,633,000 | $-54,643,000 | $-34,802,000 | $-27,923,000 |
| Gains Losses Not Affecting Retained Earnings | $81,000 | $0 | - | - |
| Other Equity Adjustments | $81,000 | - | - | - |
| Retained Earnings | $-115,918,000 | $-58,327,000 | $-37,739,000 | $-30,531,000 |
| Preferred Securities Outside Stock Equity | $0 | $126,756,000 | $43,904,000 | $43,904,000 |
| Other | ||||
| Ordinary Shares Number | $21,815,353 | $21,688,172 | $21,384,377 | $21,384,377 |
| Share Issued | $21,815,353 | $21,688,172 | $21,384,377 | $21,384,377 |
| Tangible Book Value | $106,633,000 | $-54,643,000 | $-34,802,000 | $-27,923,000 |
| Invested Capital | $106,633,000 | $-54,643,000 | $-34,802,000 | $-27,923,000 |
| Working Capital | $101,338,000 | $69,210,000 | $8,986,000 | $15,896,000 |
| Capital Lease Obligations | $441,000 | $779,000 | $162,000 | $262,000 |
| Total Capitalization | $106,633,000 | $-54,643,000 | $-34,802,000 | $-27,923,000 |
| Additional Paid In Capital | $222,470,000 | $3,684,000 | $2,937,000 | $2,608,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Preferred Stock | $0 | $0 | - | - |
| Long Term Capital Lease Obligation | $0 | $441,000 | $50,000 | $162,000 |
| Current Capital Lease Obligation | $441,000 | $338,000 | $112,000 | $100,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,913,000 | $225,000 | $45,000 | $53,000 |
| Current Accrued Expenses | $5,122,000 | $1,395,000 | $190,000 | $183,000 |
| Net PPE | $355,000 | $735,000 | $155,000 | $252,000 |
| Gross PPE | $355,000 | $735,000 | $155,000 | $252,000 |
| Other Properties | $355,000 | $735,000 | $155,000 | $252,000 |
| Other Short Term Investments | $62,976,000 | $12,022,000 | $254,000 | $546,000 |
Fetched: 2026-10-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-54,267,000 | $-18,196,000 | $-5,824,000 | $-10,543,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-54,172,000 | $-18,087,000 | $-5,824,000 | $-10,543,000 |
| Cash Flow From Continuing Operating Activities | $-54,172,000 | $-18,087,000 | $-5,824,000 | $-10,543,000 |
| Operating Gains Losses | - | - | $-923,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-95,000 | $-109,000 | - | - |
| Investing Cash Flow | $-49,667,000 | $-11,998,000 | $0 | $-1,000,000 |
| Cash Flow From Continuing Investing Activities | $-49,667,000 | $-11,998,000 | $0 | $-1,000,000 |
| Net Other Investing Changes | - | - | - | $-1,000,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $91,075,000 | $85,000,000 | $0 | $225,000 |
| Financing Cash Flow | $89,249,000 | $81,991,000 | $0 | $225,000 |
| Cash Flow From Continuing Financing Activities | $89,249,000 | $81,991,000 | $0 | $225,000 |
| Net Other Financing Charges | $-2,387,000 | $-3,341,000 | - | - |
| Net Preferred Stock Issuance | $0 | $85,000,000 | $0 | - |
| Preferred Stock Issuance | $0 | $85,000,000 | $0 | - |
| Net Common Stock Issuance | $91,075,000 | $0 | $0 | $225,000 |
| Common Stock Issuance | $91,075,000 | $0 | $0 | $225,000 |
| Other | ||||
| End Cash Position | $47,051,000 | $61,641,000 | $9,735,000 | $15,559,000 |
| Beginning Cash Position | $61,641,000 | $9,735,000 | $15,559,000 | $26,877,000 |
| Changes In Cash | $-14,590,000 | $51,906,000 | $-5,824,000 | $-11,318,000 |
| Proceeds From Stock Option Exercised | $561,000 | $332,000 | $0 | $225,000 |
| Net Investment Purchase And Sale | $-49,572,000 | $-11,889,000 | $0 | - |
| Sale Of Investment | $80,027,000 | $0 | - | - |
| Purchase Of Investment | $-129,599,000 | $-11,889,000 | $0 | - |
| Net PPE Purchase And Sale | $-95,000 | $-109,000 | $0 | - |
| Purchase Of PPE | $-95,000 | $-109,000 | $0 | - |
| Change In Working Capital | $356,000 | $1,573,000 | $-81,000 | $-1,311,000 |
| Change In Other Current Liabilities | $-338,000 | $-198,000 | $-100,000 | $-101,000 |
| Change In Payables And Accrued Expense | $6,654,000 | $2,183,000 | $774,000 | $-804,000 |
| Change In Accrued Expense | $6,415,000 | $1,385,000 | $-2,000 | $-835,000 |
| Change In Payable | $239,000 | $798,000 | $776,000 | $31,000 |
| Change In Account Payable | $239,000 | $798,000 | $776,000 | $31,000 |
| Change In Prepaid Assets | $-5,960,000 | $-412,000 | $-755,000 | $-406,000 |
| Other Non Cash Items | $380,000 | $235,000 | $97,000 | $1,000,000 |
| Stock Based Compensation | $3,948,000 | $439,000 | $313,000 | $412,000 |
| Unrealized Gain Loss On Investment Securities | $5,000 | $217,000 | $1,216,000 | $2,321,000 |
| Provisionand Write Offof Assets | $0 | $117,000 | $762,000 | $489,000 |
| Amortization Of Securities | $-1,306,000 | $-96,000 | $0 | - |
| Depreciation Amortization Depletion | $36,000 | $16,000 | $0 | $110,000 |
| Depreciation And Amortization | $36,000 | $16,000 | $0 | $110,000 |
| Depreciation | $36,000 | $16,000 | $0 | $110,000 |
| Net Income From Continuing Operations | $-57,591,000 | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Gain Loss On Investment Securities | - | - | $-923,000 | - |
Fetched: 2026-10-18